Jing Wang
About
Jing Wang is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Jing Wang has authored 292 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Molecular Biology, 139 papers in Oncology and 89 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jing Wang's work include Lung Cancer Treatments and Mutations (59 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Lung Cancer Research Studies (34 papers). Jing Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (59 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Lung Cancer Research Studies (34 papers). Jing Wang collaborates with scholars based in United States, China and South Korea. Jing Wang's co-authors include Craig M. Crews, John V. Heymach, Lixia Diao, Andrew P. Crew, Hanqing Dong, Lauren A. Byers, John Hines, Yimin Qian, Ignacio I. Wistuba and Blake E. Smith and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.
In The Last Decade
Jing Wang
280 papers receiving 13.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jing Wang United States | 55 | 8.8k | 6.1k | 2.3k | 2.0k | 1.7k | 292 | 14.1k | ||
| Gideon Bollag United States | 51 | 10.1k 1.1× | 4.6k 0.8× | 1.8k 0.8× | 1.3k 0.6× | 1.7k 1.0× | 124 | 14.7k | ||
| Jeffrey R. Infante United States | 63 | 6.9k 0.8× | 9.0k 1.5× | 2.2k 1.0× | 3.5k 1.8× | 820 0.5× | 343 | 14.8k | ||
| Martin McMahon United States | 72 | 12.9k 1.5× | 7.2k 1.2× | 2.7k 1.2× | 997 0.5× | 1.9k 1.1× | 167 | 17.9k | ||
| Atanasio Pandiella Spain | 57 | 6.6k 0.7× | 4.9k 0.8× | 1.3k 0.5× | 1.2k 0.6× | 771 0.5× | 284 | 11.6k | ||
| Gary E. Gallick United States | 67 | 7.7k 0.9× | 6.0k 1.0× | 1.0k 0.4× | 2.0k 1.0× | 1.3k 0.8× | 202 | 13.7k | ||
| Elisa de Stanchina United States | 65 | 13.8k 1.6× | 7.0k 1.1× | 1.8k 0.8× | 3.0k 1.5× | 855 0.5× | 226 | 19.4k | ||
| Daniel S. Peeper Netherlands | 47 | 8.9k 1.0× | 4.6k 0.8× | 2.4k 1.0× | 905 0.5× | 1.3k 0.8× | 115 | 14.1k | ||
| Menashe Bar‐Eli United States | 68 | 6.9k 0.8× | 4.2k 0.7× | 2.9k 1.3× | 1.0k 0.5× | 940 0.6× | 186 | 12.0k | ||
| Morag Park Canada | 62 | 8.6k 1.0× | 4.0k 0.7× | 1.8k 0.8× | 1.3k 0.7× | 1.6k 1.0× | 202 | 13.4k | ||
| David Stokoe United States | 53 | 11.5k 1.3× | 3.5k 0.6× | 2.1k 0.9× | 1.2k 0.6× | 1.6k 1.0× | 96 | 15.7k |
Countries citing papers authored by Jing Wang
Since
Specialization
Citations
This map shows the geographic impact of Jing Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jing Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jing Wang more than expected).
Fields of papers citing papers by Jing Wang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jing Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jing Wang. The network helps show where Jing Wang may publish in the future.
Co-authorship network of co-authors of Jing Wang
This figure shows the co-authorship network connecting the top 25 collaborators of Jing Wang. A scholar is included among the top collaborators of Jing Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jing Wang. Jing Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhou, Yan, et al.. (2025). NRIR promotes immune escape in hepatocellular cancer by regulating IFNγ-induced PD-L1 expression. Journal of Advanced Research. 78. 423–434.
2.
Zhao, Qingnan, Jiemiao Hu, Ling‐Yuan Kong, et al.. (2023). FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nature Communications. 14(1). 735–735.
3.
Zhang, Wenli, et al.. (2023). Manipulation of valley-pseudospin in 2D WTe2/CrI3 van der Waals heterostructure by magnetic proximity effect. Applied Surface Science. 647. 158986–158986.
4.
Navarro-Yepes, Juliana, Nicole M. Kettner, Xiayu Rao, et al.. (2023). Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers. Cancer Research. 83(19). 3264–3283.
5.
Feng, Jifeng, Jing Wang, Qi Zhou, et al.. (2022). SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study. Clinical Cancer Research. 28(24). 5297–5305.
6.
Yang, Qing, Jiemiao Hu, Zhiliang Jia, et al.. (2022). Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma. Clinical Cancer Research. 28(17). 3862–3873.
7.
Sen, Triparna, B. Leticia Rodriguez, Limo Chen, et al.. (2019). Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery. 9(5). 646–661.
8.
Yan, Xiang, Xiaoshan Zhang, Li Wang, et al.. (2018). Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Research. 79(1). 125–132.
9.
Gay, Carl M., Pan Tong, Robert J. Cardnell, et al.. (2018). Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clinical Cancer Research. 25(1). 346–357.
10.
Sandulache, Vlad C., Chieko Michikawa, Frederico O. Gleber‐Netto, et al.. (2018). High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. Clinical Cancer Research. 24(7). 1727–1733.
11.
Zhang, Jiexin, Li Shen, Xiayu Rao, et al.. (2017). CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Research. 78(3). 781–797.
12.
Morris, Van K., Xiayu Rao, Curtis R. Pickering, et al.. (2017). Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Molecular Cancer Research. 15(11). 1542–1550.
13.
Balaji, Kavitha, Smruthi Vijayaraghavan, Lixia Diao, et al.. (2016). AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research. 15(1). 45–58.
14.
Wang, Yifan, Hui Liu, Lixia Diao, et al.. (2016). Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clinical Cancer Research. 22(23). 5876–5886.
15.
Sun, Kaiming, Ruzanna Atoyan, Mylissa Borek, et al.. (2016). Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers. Molecular Cancer Therapeutics. 16(2). 285–299.
16.
Lou, Yanyan, Lixia Diao, Edwin R. Parra, et al.. (2016). Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clinical Cancer Research. 22(14). 3630–3642.
17.
Cardnell, Robert J., Carmen Behrens, Lixia Diao, et al.. (2015). An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research. 21(15). 3480–3491.
18.
Nilsson, Monique B., Uma Giri, Jayanthi Gudikote, et al.. (2015). KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clinical Cancer Research. 22(8). 1940–1950.
19.
Cardnell, Robert J., Ying Feng, Lixia Diao, et al.. (2013). Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. Clinical Cancer Research. 19(22). 6322–6328.
20.
Kadara, Humam, Li Shen, Junya Fujimoto, et al.. (2012). Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling. Cancer Prevention Research. 6(1). 8–17.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gideon Bollag Breakdown of academic impact, for papers by Jeffrey R. Infante Breakdown of academic impact, for papers by Martin McMahon Breakdown of academic impact, for papers by Atanasio Pandiella Breakdown of academic impact, for papers by Gary E. Gallick Breakdown of academic impact, for papers by Elisa de Stanchina Breakdown of academic impact, for papers by Daniel S. Peeper Breakdown of academic impact, for papers by Menashe Bar‐Eli Breakdown of academic impact, for papers by Morag Park Breakdown of academic impact, for papers by David Stokoe